AstraZeneca Takes First Step For Lynparza/Imfinzi Combo In Ovarian Cancer
First PARP plus PD1/L1-inhibitor Combo Data
Executive Summary
Combining a PARP inhibitor with a checkpoint inhibitor could improve outcomes in ovarian cancer patients, hint the early data from AstraZeneca’s Phase III DUO-O study of Lynparza and Imfinzi. How much broader a market now beckons for the two drugs remains uncertain, however.
You may also be interested in...
ASCO Preview: Five Top Late-Breakers To Watch For
AstraZeneca plans to unveil multiple major data packages, while Servier reveals much-anticipated results in glioma, and ImmunoGen and Novartis will present key pivotal data in women’s cancers.
New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.
10 Approvals To Look Out For In Q3 2023
The third quarter could bring US approvals for a range of novel drugs, including the first treatment for a common eye disease, the first US approval of PD-1/L1 inhibitor from a Chinese firm, and the first oral therapy for postpartum depression.